APA (7th ed.) Citation

MWC, V., M, R., A, L., BS, R., L, S., C, B., . . . VHJ, v. d. V. (2025). Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study. HemaSphere, 9(4), e70125. https://doi.org/10.1002/hem3.70125

Chicago Style (17th ed.) Citation

MWC, Verbeek, et al. "Minimal Residual Disease Assessment Following CD19-targeted Therapy in B-cell Precursor Acute Lymphoblastic Leukemia Using Standardized 12-color Flow Cytometry: A EuroFlow Study." HemaSphere 9, no. 4 (2025): e70125. https://doi.org/10.1002/hem3.70125.

MLA (9th ed.) Citation

MWC, Verbeek, et al. "Minimal Residual Disease Assessment Following CD19-targeted Therapy in B-cell Precursor Acute Lymphoblastic Leukemia Using Standardized 12-color Flow Cytometry: A EuroFlow Study." HemaSphere, vol. 9, no. 4, 2025, p. e70125, https://doi.org/10.1002/hem3.70125.